Article
Arylazanylpyrazolone derivatives as inhibitors of mutant superoxide dismutase 1 dependent protein aggregation for the treatment of amyotrophic lateral sclerosis.
Journal of medicinal chemistry - 28 Mar 2013
Zhang Yinan, Benmohamed Radhia, Huang He, Chen Tian, Voisine Cindy, Morimoto Richard I, Kirsch Donald R, Silverman Richard B
Abstract excerpt
The arylsulfanylpyrazolone and aryloxanylpyrazolone scaffolds previously were reported to inhibit Cu/Zn superoxide dismutase 1 dependent protein aggregation and to extend survival in the ALS mouse model. However, further evaluation of these compounds indicated weak pharmacokinetic properties and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
